ViroMed is a biotechnology company located in Korea with an established pipeline targeting cardiovascular disease, cancer, and immune-related disorders.
ViroMed contacted Alaniz to assist with a 15-center nationwide recruitment campaign for a phase 3 diabetic peripheral neuropathy trial. Alaniz developed and deployed a targeted campaign that drew hundreds of highly qualified study volunteers to the research sites. ViroMed hit its study quota and ended the campaign early.